Effects of α-linolenic acid supplementation in perilla oil on collagen-epinephrine closure time, activated partial thromboplastin time and Lp-PLA2 activity in non-diabetic and hypercholesterolaemic subjects

• Published in: Journal of functional foods Vol. 23; pp. 95 - 104
• Main Authors: Kim, Minkyung, Kim, Minjoo, Lee, Young Ju, Lee, Sung Pyo, Kim, Tae Su, Yang, Hye Jeong, Kwon, Dae Young, Lee, Sang-Hyun, Lee, Jong Ho
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.05.2016
• Subjects: alpha-linolenic acid; aPTT; C-EPI CT; humans; hypercholesterolemia; low density lipoprotein cholesterol; Lp-PLA2; oxidation; Perilla oil; phospholipase A2; placebos; thromboplastin; α-linolenic acid; PFA-100; aPTT; PT; PAF-AH; apo B; ox-LDL; Lp-PLA2; BP; GC-MS; C-EPI; CT; SE; C-EPI CT; FAME; α-linolenic acid; ALA; Perilla oil; MCT
• ISSN: 1756-4646; 2214-9414
• DOI: 10.1016/j.jff.2016.02.026

•The ALA group showed greater reductions in total- and LDL-cholesterol, ox-LDL, apo B and Lp-PLA2 activity than the placebo.•The ALA group showed greater increases in plasma ALA, aPTT C-EPI CT than the placebo group.•Independent and positive correlations between changes in C-EPI CT and plasma ALA were observed.•Independent and negative correlations between changes in aPTT and Lp-PLA2 were observed.•ALA supplementation was associated with prolonged C-EPI CT and aPTT and decreased Lp-PLA2. We examined whether α-linolenic acid (ALA) alters total-cholesterol and haemostatic factors and the relationship between such alterations and lipoprotein-associated phospholipase A2 (Lp-PLA2). Eighty-six non-diabetic, borderline-to-moderate hypercholesterolaemic human subjects were divided into two groups: ALA group and placebo group. After 8 weeks of treatment, the ALA group exhibited significant increases in plasma ALA, and reductions in total- and LDL-cholesterol. The ALA group showed significantly greater reductions in total- and LDL-cholesterol, ox-LDL, apo B and Lp-PLA2 activity and greater increases in plasma ALA, activated partial thromboplastin time (aPTT) and collagen-epinephrine (C-EPI) closure time (CT) than the placebo after adjusting for baseline levels. Independent and significant correlations between changes in C-EPI CT and plasma ALA, and between changes in aPTT and Lp-PLA2, were observed. In conclusion, ALA supplementation was associated with prolonged C-EPI CT and aPTT and decreased Lp-PLA2, which were mediated by decreasing LDL-cholesterol oxidation, thereby reducing substrate available for Lp-PLA2 (ClinicalTrials.gov:NCT02609295; http://www.clinicaltrials.gov).